Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 28 Jan 2026 for Repare Therapeutics Inc..
Filing timeline
BuySaleThomas Civik
Insider track record
Disclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-51.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Thomas Civik: trading record in brief
Filings by Thomas Civik span 4 companies, the busiest being Five Prime Therapeutics Inc, Pyxis Oncology, Inc. and Foundation Medicine, Inc. We count 10 filings; the first trade dates from 1 January 2018 and the latest from 28 January 2026.
Every open-market trade on record is a purchase: 2 purchases worth €362k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants.
Most recently, on 28 January 2026, the filings show a transaction in Repare Therapeutics Inc. The most recent open-market purchase was published on 19 November 2021, 1,800 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Thomas Civik
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
7,500 sharesCommon SharesSEC:0001723092-26-000002:0
139,355 shares0Common StockSEC:0001209191-23-021404:0
66,831 shares0Common StockSEC:0001140361-22-012919:0
15,700 shares@ US$12.74100.0% of flowCommon StockSEC:0000899243-21-045363:0
Canonical exit: 16 Feb 2022 (T+90)
7,500 shares@ US$28.08100.0% of flowCommon SharesSEC:0001209191-21-065517:0
Canonical exit: 14 Feb 2022 (T+90)
5 of 5 declarations
